---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-112682"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:45:16.740525+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Therapeutics issues $143,750 note to Labrys Fund II, reports Q3 2025 results

## Summary
- Entered securities purchase agreement with Labrys Fund II for a promissory note of $143,750, including $18,750 original issue discount, receiving net proceeds of $121,500.
- Note requires six payments of $22,589 starting May 2026, matures November 10, 2026, and is convertible at 25% discount to lowest trading price over 20 days, subject to 4.99% ownership cap.
- Q3 2025 net loss was $2.1 million ($0.19 per share); cash and equivalents were $0.23 million as of September 30, 2025.
- R&D expenses were $0.9 million and G&A expenses were $1.1 million, both down from prior year quarter.
- FDA cleared Phase 3b ENDURANCE trial of NurOwn for ALS; a Citizen Petition was filed by ALS community representatives seeking renewed regulatory review.

## SEC filing metadata
- accession: 0001104659-25-112682
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465925112682/0001104659-25-112682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465925112682/tm2531319d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-112682
- JSON: https://secwatch.observer/filing/0001104659-25-112682.json
- Plain text: https://secwatch.observer/filing/0001104659-25-112682.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.